ClinicalTrials.Veeva

Menu
M

Medsol Clinical Research Center | Port Charlotte, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Eslicarbazepine Acetate
Tetrodotoxin
XEN1101
TAK-935
BIA 2-093
Soticlestat
PVP
Pregabalin
Nipocalimab
Iodine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 27 total trials

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis (ADAPT SERON)

The primary purpose of this study is to measure the efficacy and safety of efgartigimod intravenously (IV) compared to placebo in participants with A...

Enrolling
Generalized Myasthenia Gravis
Other: Placebo IV
Biological: Efgartigimod IV

The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and toler...

Enrolling
Focal Onset Seizures
Drug: XEN1101
Drug: Placebo

To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chem...

Enrolling
Chemotherapy-induced Peripheral Neuropathy
Chemotherapy-induced Neuropathic Pain
Drug: Placebo
Drug: Tetrodotoxin

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravi...

Enrolling
Myasthenia Gravis
Drug: Nipocalimab
Drug: Placebo

The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment.Participants will re...

Active, not recruiting
Dravet Syndrome (DS)
Epilepsy
Drug: Soticlestat

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Enrolling
Focal Epilepsy
Drug: BHV-7000
Drug: Placebo

The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and toler...

Active, not recruiting
Focal Epilepsy
Drug: XEN1101

This study is researching an experimental combination treatment with pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on pa...

Enrolling
Generalized Myasthenia Gravis
Drug: Pozelimab
Drug: Pozelimab + Cemdisiran

The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \& 15%) versus placebo during a 12-week treat...

Active, not recruiting
Chemotherapy-induced Peripheral Neuropathy
Drug: Placebo
Drug: ATX01 10%

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

Invitation-only
Focal Epilepsy
Drug: BHV-7000

Trial sponsors

Sumitomo Pharma logo
Takeda logo
Biohaven logo
Viatris logo
W
X
argenx logo
A
AstraZeneca logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems